explore -WSS

explore

author：Wikipedia 2025-09-29 13:31:00 - browse：6496

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Pushing for an NIH office for post

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

Steward Health Care Massachusetts hospitals face fiscal disaster

Anavex keeps shifting the goalposts in its clinical trials

Man killed during FBI raid in connection with threats against Biden, other officials

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

First U.S. drug developed to treat liver disease MASH is approved

hotspot

explore

Wikipedia

At least 13 dead in Texas as scorching temps continue

Maui's cultural, historic landmarks damaged in the devastating wildfires

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Medical leaders decry Supreme Court decision on affirmative action

South Korea throws huge K

Drug repurposing or repositioning? The language matters

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Moonlake's readout produced a cash windfall. Risks remain

How many hemophilia patients actually want gene therapy?

leisure time

FDA advisers back CAR

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Maui's cultural, historic landmarks damaged in the devastating wildfires

What to know about Virgin Galactic's 1st mission taking paying customers to space

Readout Newsletter: CAR

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Wikipedia

leisure time

knowledge

explore